Biofrontera AG: Expected impairment losses

Leverkusen (pta029/24.09.2025/23:10 UTC+2)

"Biofrontera AG: Expected impairment losses in the unconsolidated accounts amounting to approx. €50 million to €65 million, consolidated net earnings in 2025 expected to be around €5 million lower

As of today, the Management Board expects, with a high degree of likelihood, that Biofrontera AG will be required to recognize a significant write-down in ist unconsolidated accounts on the valuations of its subsidiaries, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH, in an amount expected to range between €50 million and €65 million.

Based on the current information regarding associated risks across the different markets, the management has reduced the profit expectations of both subsidiaries. The downward revision of expected profitability has a direct impact on the carrying value of the investments and, consequently, on the equity of Biofrontera AG. The exact amount of the write-down will be determined in the course of preparing the unconsolidated financial statements as of December 31, 2025.

In addition, the reduction in projected future results adversely affects the recoverability of deferred tax assets, which will result in a negative impact on the Group's net consolidated results (IFRS) by presumably around €5 million.

None of these effects will impact consolidated EBITDA for 2025, either at half-year or year-end 2025, and will not affect the Company's cash position."

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor Relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	ir@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE000A4BGGM7 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate